MedTrace Logo

Second Primary Lung Cancer Cohort Study (SPORT)

NCT04178889 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 850

Last updated 2021-03-25

No results posted yet for this study

Summary

Patients who have had curative treatment for lung cancer are at an increased risk of developing second primary lung cancers (and other cancers) over the next 10 years. Doctors need to develop better ways of monitoring patients during follow up so we can intervene as quickly as possible with further treatments. Measuring DNA in the blood which has come from the tumour, so called circulating tumour DNA (ctDNA), may be one way to do this.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Robert Rintoul, PhD FRCP · Royal Papworth Hospital NHS Trust

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04178889 on ClinicalTrials.gov